Lexicon Pharmaceuticals (LXRX) News Today $0.73 +0.06 (+9.27%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Nantahala Capital Management LLC Acquires 4,300,000 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Nantahala Capital Management LLC grew its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 186.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,604,150 shares of the bApril 30 at 8:15 AM | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus Target Price from AnalystsApril 29 at 1:21 AM | americanbankingnews.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by AnalystsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned a consensus recommendation of "Hold" from the five brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommApril 28 at 4:28 AM | marketbeat.comLexicon Pharmaceuticals (LXRX) to Post Quarterly Earnings on ThursdayLexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-lexicon-pharmaceuticals-inc-stock/)April 26, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at StockNews.comStockNews.com assumed coverage on Lexicon Pharmaceuticals in a research note on Monday. They issued a "sell" rating on the stock.April 22, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of Lexicon Pharmaceuticals in a report on Sunday. They set a "sell" rating for the company.April 14, 2025 | marketbeat.comStockNews.com Begins Coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX)StockNews.com started coverage on Lexicon Pharmaceuticals in a research report on Saturday. They issued a "sell" rating for the company.April 6, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest UpdateLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 39,260,000 shares, a drop of 17.3% from the February 28th total of 47,460,000 shares. Currently, 17.1% of the company's shares are sold short. Based on an average daily trading volume, of 6,260,000 shares, the days-to-cover ratio is currently 6.3 days.April 3, 2025 | marketbeat.comLexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comLexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday.March 29, 2025 | marketbeat.comLexicon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) saw unusually large options trading on Friday. Stock traders bought 2,504 call options on the company. This represents an increase of 61% compared to the average volume of 1,558 call options.March 29, 2025 | marketbeat.comStock Traders Purchase Large Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders acquired 2,504 call options on the company. This represents an increase of 61% compared to the typical volume of 1,558 call options.March 29, 2025 | marketbeat.comLexicon stock soars on Novo Nordisk licensing dealMarch 29, 2025 | za.investing.comLexicon announces exclusive license agreement with Novo Nordisk for LX9851March 29, 2025 | markets.businessinsider.comLexicon announces exclusive license agreement with Novo Nordisk for LX9851March 29, 2025 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Lexicon PharmaceuticalsMarch 29, 2025 | benzinga.comWhat 6 Analyst Ratings Have To Say About Lexicon PharmaceuticalsMarch 29, 2025 | benzinga.comLexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensing DealMarch 28, 2025 | gurufocus.comPenny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo NordiskMarch 28, 2025 | benzinga.comPenny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo NordiskMarch 28, 2025 | benzinga.comLexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851March 28, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on Lexicon Pharmaceuticals in a research report on Thursday. They issued a "sell" rating for the company.March 20, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for LXRX Q1 Earnings?Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per sharMarch 11, 2025 | marketbeat.comEquities Analysts Issue Forecasts for LXRX Q1 EarningsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnMarch 10, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by BrokeragesLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a bMarch 8, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Cut to $6.00 by Analysts at Piper SandlerPiper Sandler cut their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday.March 8, 2025 | marketbeat.comLexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and ChallengesMarch 7, 2025 | tipranks.comLexicon Pharmaceuticals (NASDAQ:LXRX) Issues Earnings Results, Beats Expectations By $0.02 EPSLexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%.March 7, 2025 | marketbeat.comLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025March 7, 2025 | gurufocus.comLexicon Pharmaceuticals (NASDAQ:LXRX) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSLexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%.March 7, 2025 | marketbeat.comLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025March 7, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday.March 7, 2025 | marketbeat.comLexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...March 7, 2025 | gurufocus.comQ4 2024 Lexicon Pharmaceuticals Inc Earnings Call TranscriptMarch 7, 2025 | gurufocus.comLexicon Pharmaceuticals Advances Pipeline Amid Financial GrowthMarch 6, 2025 | tipranks.comLexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comLexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 6, 2025 | globenewswire.comLeerink Partners Downgrades Lexicon Pharmaceuticals (LXRX)March 5, 2025 | msn.comLeerink Partners Reiterates Market Perform Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Leerink Partners reiterated a "market perform" rating and set a $1.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday.March 5, 2025 | marketbeat.comLexicon Pharmaceuticals Q4 2024 Earnings PreviewMarch 5, 2025 | seekingalpha.comLexicon downgraded to Market Perform from Outperform at LeerinkMarch 4, 2025 | markets.businessinsider.comLexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025March 4, 2025 | globenewswire.comH.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)March 4, 2025 | markets.businessinsider.comLexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday.March 3, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday.March 3, 2025 | marketbeat.comLexicon stock plummets following Phase 2b study resultsMarch 3, 2025 | au.investing.comLexicon Pharmaceuticals stock tumbles after clinical study resultsMarch 3, 2025 | in.investing.comLexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?March 3, 2025 | benzinga.comLexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic PainMarch 3, 2025 | globenewswire.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.830.85▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼54▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZBIO News VSTM News RIGL News EBS News XOMA News VNDA News RGLS News CDXS News SGMO News IRWD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXRX Stock Free LXRX Stock Alerts